晚期胆管细胞癌能否成为可治疗的恶性肿瘤？

Will advanced cholangiocarcinoma become a targetable malignancy?

机构信息

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

出版信息

Crit Rev Oncol Hematol. 2021 Mar;159:103233. doi: 10.1016/j.critrevonc.2021.103233. Epub 2021 Jan 19.

DOI:10.1016/j.critrevonc.2021.103233

Abstract

Cholangiocarcinoma and biliary tract cancers are rare but aggressive tumors that are characterized by an heterogenous molecular and genetic footprint. Genetic aberrations such as FGFR2 fusion and ErBb2 amplification are common in those cancers. Recent studies aimed at exploring the efficacy and benefit of targeted therapy in the treatment of advanced cholangiocarcinoma. Many promising drugs exist and warrant additional investigations. This review will summarize available results and highlight therapeutic strategies incorporated in clinical trials.

摘要

胆管癌和胆道癌是罕见但侵袭性很强的肿瘤，其特征是具有异质性的分子和遗传特征。FGFR2 融合和 ErBb2 扩增等遗传异常在这些癌症中很常见。最近的研究旨在探索靶向治疗在晚期胆管癌治疗中的疗效和益处。有许多有前途的药物存在，并需要进一步研究。本文综述了现有研究结果，并强调了临床试验中采用的治疗策略。